Hassan Alfanharawi, Prabhpreet S Bassi, Christina D Enescu, Siri S Sarvepalli, Victor Ajluni
{"title":"Late-onset multiple sclerosis initially presenting with acute psychiatric symptomatology: A case report.","authors":"Hassan Alfanharawi, Prabhpreet S Bassi, Christina D Enescu, Siri S Sarvepalli, Victor Ajluni","doi":"10.12788/acp.0038","DOIUrl":"https://doi.org/10.12788/acp.0038","url":null,"abstract":"","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 3","pages":"208-209"},"PeriodicalIF":1.3,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39328173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmed Aboraya, Henry A Nasrallah, Daniel Elswick, Yasha Rastgar, James Berry, Cheryl Hill, John Justice, Wanhong Zheng, Nathan Pearson, Gerard Gallucci, Patricia Figgs, Jeremy Hustead, Joel Vogt, Jawad Zafar, Sheena Dohar, Robert Looper, Danielle Guinan, Akram Elawady, Omar Shah, Mei Wai Lam, Shanila Shagufta, Noah Schwartzman, Eddie Hamric, Lauren Mayle, Mark Miller, Dilip Chandran, Patrick Marshalek, Rachel Moreland, Tenchee Lama Tamang, Sunny Mattancheril, Sara Berzingi
Background: Recent literature shows that most practicing psychiatrists do not receive training in measurement-based care (MBC). Among the primary barriers to MBC implementation are the lack of formal training and curriculums. We present the first comprehensive MBC curriculum for use in adult psychiatric practice, and describe how the curriculum is adapted and implemented in psychiatry residency training programs.
Methods: The Standard for Clinicians' Interview in Psychiatry (SCIP) was developed as a measurement-based care tool for clinicians' use. The SCIP is the only instrument that includes 18 reliable and validated clinician-rated scales covering most adult psychiatric disorders. The SCIP has simple, unified rules of measurement that apply to the 18 scales. The MBC curriculum includes 2 instruction manuals, 4 didactic lectures, and 12 videotaped interviews. We describe the annual learning and implementation of MBC curriculum in residency programs.
Results: The curriculum implementation at West Virginia University and Delaware Psychiatric Center began in 2019 and is ongoing. We present 3 case demonstrations of the implementation of MBC in clinical settings.
Conclusions: Comprehensive implementation of MBC curriculum in residency programs has the potential to facilitate research and create a "culture" of MBC in future generations of psychiatrists.
{"title":"Measurement-based care training curriculum in psychiatry residency programs: I: Description of the curriculum and demonstration of implementation.","authors":"Ahmed Aboraya, Henry A Nasrallah, Daniel Elswick, Yasha Rastgar, James Berry, Cheryl Hill, John Justice, Wanhong Zheng, Nathan Pearson, Gerard Gallucci, Patricia Figgs, Jeremy Hustead, Joel Vogt, Jawad Zafar, Sheena Dohar, Robert Looper, Danielle Guinan, Akram Elawady, Omar Shah, Mei Wai Lam, Shanila Shagufta, Noah Schwartzman, Eddie Hamric, Lauren Mayle, Mark Miller, Dilip Chandran, Patrick Marshalek, Rachel Moreland, Tenchee Lama Tamang, Sunny Mattancheril, Sara Berzingi","doi":"10.12788/acp.0039","DOIUrl":"https://doi.org/10.12788/acp.0039","url":null,"abstract":"<p><strong>Background: </strong>Recent literature shows that most practicing psychiatrists do not receive training in measurement-based care (MBC). Among the primary barriers to MBC implementation are the lack of formal training and curriculums. We present the first comprehensive MBC curriculum for use in adult psychiatric practice, and describe how the curriculum is adapted and implemented in psychiatry residency training programs.</p><p><strong>Methods: </strong>The Standard for Clinicians' Interview in Psychiatry (SCIP) was developed as a measurement-based care tool for clinicians' use. The SCIP is the only instrument that includes 18 reliable and validated clinician-rated scales covering most adult psychiatric disorders. The SCIP has simple, unified rules of measurement that apply to the 18 scales. The MBC curriculum includes 2 instruction manuals, 4 didactic lectures, and 12 videotaped interviews. We describe the annual learning and implementation of MBC curriculum in residency programs.</p><p><strong>Results: </strong>The curriculum implementation at West Virginia University and Delaware Psychiatric Center began in 2019 and is ongoing. We present 3 case demonstrations of the implementation of MBC in clinical settings.</p><p><strong>Conclusions: </strong>Comprehensive implementation of MBC curriculum in residency programs has the potential to facilitate research and create a \"culture\" of MBC in future generations of psychiatrists.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 3","pages":"168-179"},"PeriodicalIF":1.3,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39328169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: COVID-19 rapidly spread worldwide with high morbidity and mortality. In this study, we aimed to detect parental concerns along with their awareness of and attitudes towards COVID-19 among patients admitted to our inpatient and outpatient clinics.
Methods: This study was conducted at a children's hospital with 141 parents of children who were patients in the inpatient and outpatient clinics. Parents were asked to complete an anonymous questionnaire and psychiatric scales that included the Beck Depression Inventory, Beck Anxiety Inventory (BAI), and Impact of Events Scale-Revised form (IES-R).
Results: The study sample consisted of 141 parents, of which 59 were parents of inpatients and 82 were parents of outpatients. The most known COVID-19 symptoms were fever, difficulty in breathing, and cough, respectively. The most preferred precaution was "staying at home." We found a significant positive correlation between the number of precautions and BAI score (R = .169, P = .046). Inpatients' parents IES-R scores were significantly higher than outpatients' parents IES-R scores.
Conclusions: Parents were found to be aware of the COVID-19 pandemic regardless of education status and family income. Participants' IES-R scores revealed significant differences in terms of COVID-19 impact on psychological health between the parents of inpatient and outpatient children; inpatients' parents were more concerned about COVID-19.
背景:COVID-19在全球范围内迅速传播,发病率和死亡率高。在本研究中,我们旨在了解住院和门诊患者中父母的担忧以及他们对COVID-19的认识和态度。方法:本研究在某儿童医院对141名住院和门诊儿童的家长进行研究。父母被要求完成一份匿名问卷和精神病学量表,包括贝克抑郁量表、贝克焦虑量表(BAI)和事件影响量表修订表(IES-R)。结果:研究样本共141名家长,其中住院患者家长59名,门诊患者家长82名。最常见的新冠肺炎症状分别是发烧、呼吸困难和咳嗽。最受欢迎的预防措施是“待在家里”。我们发现预防措施数量与BAI评分呈显著正相关(R = 0.169, P = 0.046)。住院患者父母IES-R得分显著高于门诊患者父母IES-R得分。结论:无论受教育程度和家庭收入如何,家长对COVID-19大流行的了解程度都不高。参与者的IES-R得分显示,住院和门诊儿童的父母在COVID-19对心理健康的影响方面存在显著差异;住院患者家长更关心新冠肺炎。
{"title":"An exploration of parental awareness, knowledge, and concerns related to COVID-19.","authors":"Eyüp Sarı, Harun Terin, Sadettin Burak Açıkel, Bilge Akkaya, Saliha Şenel","doi":"10.12788/acp.0040","DOIUrl":"https://doi.org/10.12788/acp.0040","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 rapidly spread worldwide with high morbidity and mortality. In this study, we aimed to detect parental concerns along with their awareness of and attitudes towards COVID-19 among patients admitted to our inpatient and outpatient clinics.</p><p><strong>Methods: </strong>This study was conducted at a children's hospital with 141 parents of children who were patients in the inpatient and outpatient clinics. Parents were asked to complete an anonymous questionnaire and psychiatric scales that included the Beck Depression Inventory, Beck Anxiety Inventory (BAI), and Impact of Events Scale-Revised form (IES-R).</p><p><strong>Results: </strong>The study sample consisted of 141 parents, of which 59 were parents of inpatients and 82 were parents of outpatients. The most known COVID-19 symptoms were fever, difficulty in breathing, and cough, respectively. The most preferred precaution was \"staying at home.\" We found a significant positive correlation between the number of precautions and BAI score (R = .169, P = .046). Inpatients' parents IES-R scores were significantly higher than outpatients' parents IES-R scores.</p><p><strong>Conclusions: </strong>Parents were found to be aware of the COVID-19 pandemic regardless of education status and family income. Participants' IES-R scores revealed significant differences in terms of COVID-19 impact on psychological health between the parents of inpatient and outpatient children; inpatients' parents were more concerned about COVID-19.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 3","pages":"180-186"},"PeriodicalIF":1.3,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39328170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Approximately 5% of hospital chief executive officers are physicians, and that number is growing. Leadership is a vital skill for future physicians.
Methods: We conducted a narrative review of the literature on student leadership in medical school and its implications for health care and policy-making.
Results: Qualities a good leader should possess include accountability, empathy, positivity, teamwork, and organization. Leadership skills need to be taught to students in their formative pre-clinical years so they can build upon this foundation during their clinical and residency years. Leadership is a multifaceted quality because unlike other lessons, it cannot be measured on a scale or under the microscope; it is largely developed through practice. Furthermore, among physicians, psychiatrists are especially well-trained to serve in active leadership roles because psychiatry training emphasizes interpersonal dynamics and emotional intelligence, qualities that are vital to the skill set of an effective leader.
Conclusions: Medical leadership is essential because physicians relate best to other physicians, and those adept in administrative skills can help bridge the gap between administration and clinicians. There is a need for teaching an evidence-based leadership curriculum and training techniques that will fill a recognized educational void in medical student education (as well as for residents and junior faculty).
{"title":"Student leadership in medical school and its implications for health care and policy-making.","authors":"Nagy A Youssef, Isha Dabke","doi":"10.12788/acp.0027","DOIUrl":"https://doi.org/10.12788/acp.0027","url":null,"abstract":"<p><strong>Background: </strong>Approximately 5% of hospital chief executive officers are physicians, and that number is growing. Leadership is a vital skill for future physicians.</p><p><strong>Methods: </strong>We conducted a narrative review of the literature on student leadership in medical school and its implications for health care and policy-making.</p><p><strong>Results: </strong>Qualities a good leader should possess include accountability, empathy, positivity, teamwork, and organization. Leadership skills need to be taught to students in their formative pre-clinical years so they can build upon this foundation during their clinical and residency years. Leadership is a multifaceted quality because unlike other lessons, it cannot be measured on a scale or under the microscope; it is largely developed through practice. Furthermore, among physicians, psychiatrists are especially well-trained to serve in active leadership roles because psychiatry training emphasizes interpersonal dynamics and emotional intelligence, qualities that are vital to the skill set of an effective leader.</p><p><strong>Conclusions: </strong>Medical leadership is essential because physicians relate best to other physicians, and those adept in administrative skills can help bridge the gap between administration and clinicians. There is a need for teaching an evidence-based leadership curriculum and training techniques that will fill a recognized educational void in medical student education (as well as for residents and junior faculty).</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 3","pages":"187-192"},"PeriodicalIF":1.3,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39328171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana M Lupu, Kathryn L MacCamy, Jessica M Gannon, Jaspreet S Brar, K N Roy Chengappa
Background: Long-term prescribing of anticholinergic medications (ACM) for antipsychotic-associated extrapyramidal symptoms (EPS) is not recommended, yet is widely prevalent. Adverse effects of ACM include memory impairment, dry mouth, constipation, blurred vision, urinary retention, and tachycardia, which can seriously impact quality of life. This quality improvement deprescription project sought to reduce chronic ACM use in patients with serious mental illness (SMI).
Methods: Education directed at psychiatrists combined with clinical pharmacy support for deprescription was used to target clinically stable patients diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with no EPS and ACM prescriptions of ≥6 months. Scales were used to assess anticholinergic adverse effects, memory impairment, and quality of life. ACMs were tapered and discontinued over 1 to 6 months.
Results: More than 75% of targeted patients successfully tapered or discontinued ACM, which coincided with significant improvements in anticholinergic adverse effects, memory impairment, and quality of life. Approximately 10% of patients were restarted on ACM for re-emergent EPS.
Conclusions: For most clinically stable patients with SMI without EPS, our findings suggest that gradual deprescription of chronic ACM is clinically appropriate, well tolerated, and improves quality of life. A randomized trial could provide more definitive answers.
{"title":"Less is more: Deprescribing anticholinergic medications in persons with severe mental illness.","authors":"Ana M Lupu, Kathryn L MacCamy, Jessica M Gannon, Jaspreet S Brar, K N Roy Chengappa","doi":"10.12788/acp.0019","DOIUrl":"https://doi.org/10.12788/acp.0019","url":null,"abstract":"<p><strong>Background: </strong>Long-term prescribing of anticholinergic medications (ACM) for antipsychotic-associated extrapyramidal symptoms (EPS) is not recommended, yet is widely prevalent. Adverse effects of ACM include memory impairment, dry mouth, constipation, blurred vision, urinary retention, and tachycardia, which can seriously impact quality of life. This quality improvement deprescription project sought to reduce chronic ACM use in patients with serious mental illness (SMI).</p><p><strong>Methods: </strong>Education directed at psychiatrists combined with clinical pharmacy support for deprescription was used to target clinically stable patients diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with no EPS and ACM prescriptions of ≥6 months. Scales were used to assess anticholinergic adverse effects, memory impairment, and quality of life. ACMs were tapered and discontinued over 1 to 6 months.</p><p><strong>Results: </strong>More than 75% of targeted patients successfully tapered or discontinued ACM, which coincided with significant improvements in anticholinergic adverse effects, memory impairment, and quality of life. Approximately 10% of patients were restarted on ACM for re-emergent EPS.</p><p><strong>Conclusions: </strong>For most clinically stable patients with SMI without EPS, our findings suggest that gradual deprescription of chronic ACM is clinically appropriate, well tolerated, and improves quality of life. A randomized trial could provide more definitive answers.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 2","pages":"80-92"},"PeriodicalIF":1.3,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9878191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joanne Jf Wang, Sarah Lin, John R Best, Robert R Selles, S Evelyn Stewart
Background: Influences of race and ethnicity have received limited attention in pediatric obsessive-compulsive disorder (OCD), despite noted importance in other psychiatric diseases. We sought to compare racially defined groups presenting to a North American tertiary care pediatric OCD subspecialty clinic.
Methods: Clinician-rated and parent/child-reported information was extracted from a research data registry comprising OCD-affected youth assessed between 2011 and 2018. The study population was aggregated into racial groups, defined as Caucasian, Asian, and "other." Country of origin and spoken language were used as ethnicity proxies. Obsessivecompulsive disorder phenotype, clinical course, and family environment were compared, with inclusion of mixed Asian-Caucasians in post-hoc analyses.
Results: Asian youth reported significantly later ages of OCD symptom onset, clinical diagnosis, and treatment compared with Caucasian youth and were significantly less likely to have participated in OCD-specific treatment, despite similar clinician recommendation rates. Obsessivecompulsive disorder severity and comorbidities did not differ across groups. Asian parents reported significantly higher levels of family blame and conflict than Caucasian parents, but similar prevalence of OCD family history.
Conclusions: Clinically relevant differences were identified between Asians and Caucasians, highlighting the need for individualized care that respects the influences of ethnicity and race in pediatric OCD. Replication and future study of additional racial groups is warranted.
{"title":"Race and ethnicity in pediatric OCD: An exploratory study of a clinical North American sample.","authors":"Joanne Jf Wang, Sarah Lin, John R Best, Robert R Selles, S Evelyn Stewart","doi":"10.12788/acp.0007","DOIUrl":"https://doi.org/10.12788/acp.0007","url":null,"abstract":"<p><strong>Background: </strong>Influences of race and ethnicity have received limited attention in pediatric obsessive-compulsive disorder (OCD), despite noted importance in other psychiatric diseases. We sought to compare racially defined groups presenting to a North American tertiary care pediatric OCD subspecialty clinic.</p><p><strong>Methods: </strong>Clinician-rated and parent/child-reported information was extracted from a research data registry comprising OCD-affected youth assessed between 2011 and 2018. The study population was aggregated into racial groups, defined as Caucasian, Asian, and \"other.\" Country of origin and spoken language were used as ethnicity proxies. Obsessivecompulsive disorder phenotype, clinical course, and family environment were compared, with inclusion of mixed Asian-Caucasians in post-hoc analyses.</p><p><strong>Results: </strong>Asian youth reported significantly later ages of OCD symptom onset, clinical diagnosis, and treatment compared with Caucasian youth and were significantly less likely to have participated in OCD-specific treatment, despite similar clinician recommendation rates. Obsessivecompulsive disorder severity and comorbidities did not differ across groups. Asian parents reported significantly higher levels of family blame and conflict than Caucasian parents, but similar prevalence of OCD family history.</p><p><strong>Conclusions: </strong>Clinically relevant differences were identified between Asians and Caucasians, highlighting the need for individualized care that respects the influences of ethnicity and race in pediatric OCD. Replication and future study of additional racial groups is warranted.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 1","pages":"4-17"},"PeriodicalIF":1.3,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38546656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica M Gannon, Abigail Schlesinger, Jody Glance, Mandayam Sujata, Noreen Fredrick, James Wyler, Gina Perez
Background: The coronavirus disease 2019 (COVID-19) pandemic brought many challenges to patient care delivery. The need for social distancing and relaxing of federal and state telemental health regulations paved the way for widespread adoption of direct-to-consumer (DTC) ambulatory mental health video visits.
Methods: We present cases that demonstrate the use of video visits across 6 clinical areas, each serving a unique population of patients, in a large behavioral health system. The benefits and limitations of this modality are illustrated in children, adults, and older adults with mood disorders, anxiety disorders, intellectual disability, substance use disorders, neurocognitive disorders, and schizophrenia.
Results: Although telephone visits were acceptable and necessary to serve some patients, there are many advantages to video visits in providing best patient care. Education and support for telemental health-delivered to both patients and clinicians-is critical to the success of the DTC model.
Conclusions: DTC telemental health is a widespread clinical tool used during the COVID-19 pandemic. Because this model has many strengths and advantages compared with traditional telemental health delivered in a clinic, regulators and insurers should be open to its continued use postpandemic when clinically appropriate.
{"title":"Rapid expansion of direct-to-consumer telemental health during the COVID-19 pandemic: A case series.","authors":"Jessica M Gannon, Abigail Schlesinger, Jody Glance, Mandayam Sujata, Noreen Fredrick, James Wyler, Gina Perez","doi":"10.12788/acp.0020","DOIUrl":"https://doi.org/10.12788/acp.0020","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) pandemic brought many challenges to patient care delivery. The need for social distancing and relaxing of federal and state telemental health regulations paved the way for widespread adoption of direct-to-consumer (DTC) ambulatory mental health video visits.</p><p><strong>Methods: </strong>We present cases that demonstrate the use of video visits across 6 clinical areas, each serving a unique population of patients, in a large behavioral health system. The benefits and limitations of this modality are illustrated in children, adults, and older adults with mood disorders, anxiety disorders, intellectual disability, substance use disorders, neurocognitive disorders, and schizophrenia.</p><p><strong>Results: </strong>Although telephone visits were acceptable and necessary to serve some patients, there are many advantages to video visits in providing best patient care. Education and support for telemental health-delivered to both patients and clinicians-is critical to the success of the DTC model.</p><p><strong>Conclusions: </strong>DTC telemental health is a widespread clinical tool used during the COVID-19 pandemic. Because this model has many strengths and advantages compared with traditional telemental health delivered in a clinic, regulators and insurers should be open to its continued use postpandemic when clinically appropriate.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 1","pages":"27-34"},"PeriodicalIF":1.3,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25322592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Naista Zhand, Philip Harvey, Roisin Osborne, Anna Hatko, Marika Stuyt, Alain Labelle
Background: Adjunctive psychostimulants have been proposed as a potential treatment option for the management of cognitive and/or negative symptoms of schizophrenia.
Methods: The present study is a retrospective review of use of adjunctive psychostimulants among outpatients enrolled in our tertiary Schizophrenia Program between 2014 and 2019. We assessed response to treatment, adverse effects, and the impact of various clinical factors on treatment outcome.
Results: Of the 77 (out of 1,300) participants prescribed psychostimulants during the study period, 42.22% had chart-based evidence of significant improvement, 27.77% had minimal improvement, and 25.55% reported no change. The majority (61.9%) demonstrated improvement in attention, concentration, and/or other cognitive symptoms. Approximately one-third of cases had evidence of emergence of psychosis. Of the factors assessed, comorbid attention-deficit/hyperactivity disorder was associated with an increased likelihood of response, and higher doses of stimulants were associated with likelihood of emergence of psychosis.
Conclusions: Adjunctive psychostimulants could be a potential treatment consideration to address cognitive deficits in selected patients with schizophrenia.
{"title":"Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.","authors":"Naista Zhand, Philip Harvey, Roisin Osborne, Anna Hatko, Marika Stuyt, Alain Labelle","doi":"10.12788/acp.0015","DOIUrl":"https://doi.org/10.12788/acp.0015","url":null,"abstract":"<p><strong>Background: </strong>Adjunctive psychostimulants have been proposed as a potential treatment option for the management of cognitive and/or negative symptoms of schizophrenia.</p><p><strong>Methods: </strong>The present study is a retrospective review of use of adjunctive psychostimulants among outpatients enrolled in our tertiary Schizophrenia Program between 2014 and 2019. We assessed response to treatment, adverse effects, and the impact of various clinical factors on treatment outcome.</p><p><strong>Results: </strong>Of the 77 (out of 1,300) participants prescribed psychostimulants during the study period, 42.22% had chart-based evidence of significant improvement, 27.77% had minimal improvement, and 25.55% reported no change. The majority (61.9%) demonstrated improvement in attention, concentration, and/or other cognitive symptoms. Approximately one-third of cases had evidence of emergence of psychosis. Of the factors assessed, comorbid attention-deficit/hyperactivity disorder was associated with an increased likelihood of response, and higher doses of stimulants were associated with likelihood of emergence of psychosis.</p><p><strong>Conclusions: </strong>Adjunctive psychostimulants could be a potential treatment consideration to address cognitive deficits in selected patients with schizophrenia.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 1","pages":"45-52"},"PeriodicalIF":1.3,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25322594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TO THE EDITOR: We report a case of a 40-year-old female patient with a medical history of chronic refractory urticaria who presented with intractable migraine and adult-onset stuttering. The patient’s stuttering was characterized by a sudden onset and prolonging of words with repetition of beginning syllables, and it was associated with anxiety and migraine. There was no personal or known family history of stuttering. The patient reported her stuttering began more than 2 years ago, when she was prescribed cyproheptadine, 12 mg/d, for autoimmune urticaria flares. This medication was discontinued approximately 5 months later due to weight gain and possible contribution to stuttering, but the stuttering did not improve. Multiple other treatment options had been previously explored, including propranolol, topiramate, IV steroids, dihydroergotamine, and butalbital-acetaminophen-caffeine combination medication, but these were ineffective. Magnetic resonance imaging and venography of the brain demonstrated a partially visualized left multispacial vascular malformation, but were otherwise unremarkable. Given the patient's extensive history of migraine medication failures, the patient’s neurologist administered erenumab, 70 mg, a new autoimmune treatment for migraine. Erenumab is a monoclonal antibody that antagonizes the calcitonin gene-related peptide (CGRP) receptor and is approved for use as migraine prophylaxis. The patient reported relief of migraine and stuttering within 2 days of treatment and remained free of symptoms for 1 month. The stuttering returned by the time of the next erenumab dose, which the patient had delayed to better understand the treatment’s effects on her migraine and stuttering. After the second dose of erenumab was administered, she again experienced improvements in both the prevention of her migraine and treatment of her stuttering symptoms.
{"title":"Migraine and adult-onset stuttering: A proposed autoimmune phenomenon.","authors":"Stephanie M Wong, Joyce Y Kim, Gerald A Maguire","doi":"10.12788/acp.0016","DOIUrl":"https://doi.org/10.12788/acp.0016","url":null,"abstract":"TO THE EDITOR: We report a case of a 40-year-old female patient with a medical history of chronic refractory urticaria who presented with intractable migraine and adult-onset stuttering. The patient’s stuttering was characterized by a sudden onset and prolonging of words with repetition of beginning syllables, and it was associated with anxiety and migraine. There was no personal or known family history of stuttering. The patient reported her stuttering began more than 2 years ago, when she was prescribed cyproheptadine, 12 mg/d, for autoimmune urticaria flares. This medication was discontinued approximately 5 months later due to weight gain and possible contribution to stuttering, but the stuttering did not improve. Multiple other treatment options had been previously explored, including propranolol, topiramate, IV steroids, dihydroergotamine, and butalbital-acetaminophen-caffeine combination medication, but these were ineffective. Magnetic resonance imaging and venography of the brain demonstrated a partially visualized left multispacial vascular malformation, but were otherwise unremarkable. Given the patient's extensive history of migraine medication failures, the patient’s neurologist administered erenumab, 70 mg, a new autoimmune treatment for migraine. Erenumab is a monoclonal antibody that antagonizes the calcitonin gene-related peptide (CGRP) receptor and is approved for use as migraine prophylaxis. The patient reported relief of migraine and stuttering within 2 days of treatment and remained free of symptoms for 1 month. The stuttering returned by the time of the next erenumab dose, which the patient had delayed to better understand the treatment’s effects on her migraine and stuttering. After the second dose of erenumab was administered, she again experienced improvements in both the prevention of her migraine and treatment of her stuttering symptoms.","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 1","pages":"56-57"},"PeriodicalIF":1.3,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25322595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}